Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iExosomes in Metastatic Pancreatic Cancer with KrasG12D Mutation
NCT03608631Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stromal cells-derived exosomes with kras g12d sirna in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Dose-Limiting Toxicities at 4 weeks and 3 more. Started Jan 2021; status: recruiting.
02
Drugs
mesenchymal stromal cells-derived exosomes with kras g12d sirna
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03608631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608631.